A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma

Pediatric Blood and Cancer

Volumn 63, Issue 1, 2016, Pages 39-46

  Mitchell, Deanna ^a,b   Bergendahl, Genevieve ^a   Ferguson, William ^c   Roberts, William ^d   Higgins, Timothy ^e   Ashikaga, Takamaru ^f   Desarno, Mike ^f   Kaplan, Joel ^g   Kraveka, Jacqueline ^h   Eslin, Don ⁱ   Werff, Alyssa Vander ^a   Hanna, Gina K ^j   Sholler, Giselle L Saulnier ^a,b  

^a HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g Levine Children's Hospital   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Brain tumors; Medulloblastoma; Neuroblastoma; Pediatric hematology oncology; Phase I clinical trials; TPI 287

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; TEMOZOLOMIDE; TPI 287; UNCLASSIFIED DRUG; DACARBAZINE; TAXOID; TPI-287;

ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DEHYDRATION; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; FATIGUE; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPOKALEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER DYSFUNCTION; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEIZURE; SENSORY NEUROPATHY; STRESS FRACTURE; TREATMENT RESPONSE; VOMITING; YOUNG ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; PRESCHOOL CHILD; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; TAXOIDS;

EID: 84951568617     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25687     Document Type: Article

References (31)

1. Society AC . Cancer facts and figures. Atlanta, GA: American Cancer Society; 2008.
2. Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L, Shuster J, Byrne T, Gregory D, Hill G, Dougherty G, Scriver C, Lemieux B, Tuchman M, Woods WG. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992; 10:323-329.
3. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477.
4. Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin North Am 2008; 55:97-120.
5. Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R, Couanet D, Lumbroso J, Benhamou E. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23:789-795.
6. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Eng J Med 1999; 341:1165-1173.
7. (CBTRUS) CBTRotUS. 2007-2008 Primary Brain Tumors of the United States. 2008:2000-2004 (Years Data Collected).
8. Partap S, Fisher PG. Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr 2007; 19:670-674.
9. Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, Von Hoff DD. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3:1769-1774.
10. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6:998-1007.
11. Emerson DL, Bell C, Jones ME, Schiemann B, Tapolsky G. Oral bioavailabity and antitumor activity of TPI 287 a new taxane analog with greater activity than paclitaxel against tumor cells with demonstrated mutant tubulin. AACR Meeting Abstracts 2006; 2006:116-b-117.
12. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 2012; 11:1959-1967.
13. Emerson D, Jones M, Bell C, Brown E. TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice. AACR Meeting Abstracts 2007:1441.
14. Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 2010; 70:5870-5879.
15. Modiano MR, Plezia P, Basche M, Cohn AL, Baram Y, Tapolsky G, Yancik S, Pugliese L, Silberman S. A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer. ASCO Meeting Abstracts 2008; 26:13510.
16. Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson AD. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998; 78:652-661.
17. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J Clin Oncol 1998; 16:3037-3043.
18. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006; 42:2335-2342.
19. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: A pediatric brain tumor consortium report. Clin Cancer Res 2007; 13:6712-6718.
20. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
21. Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Auvrignon A, Djafari L, Hobson R, Baunin C, Dickinson F, Brisse H, McHugh K, Biassoni L, Giammarile F, Vassal G, Societe Francaisedes Cancers de lE, United Kingdom Children Cancer Study Group-New Agents Group S. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 2006; 24:5259-5264.
22. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, Force IT. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009; 27:289-297.
23. Seibel NL, Reaman GH. New microtubular agents in pediatric oncology. Invest New Drugs 1996; 14:49-54.
24. Andre N, Meille C. Taxanes in paediatric oncology: And now? Cancer Treat Rev 2006; 32:65-73.
25. Irizarry L, Luu TH, McKoy JM, Samaras AT, Fishe MJ, Carias EE, Raisch DW, Calhoun EA, Bennett CL. Cremophor EL-containing paclitaxel induced anaphylaxis: A call to action. Community Oncol 2009; 6:132-134.
26. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
27. Smolinske SC. Handbook of food, drug, and cosmetic excipients. Boca Raton: CRC Press; 1992. p. 439.
28. Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp 2014; 76:90-97.
29. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
30. Saulnier Sholler GL, Bergendahl G, Lenox S, Zage PE, Roberts W, Kraveka JM, Eslin D, Kaplan J, Higgins T, Ferguson W. A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma. ASCO Meeting Abstracts 2010; 28:TPS329.
31. Saulnier Sholler GL, Eslin D, Roberts WD, Kaplan J, Bergendahl G, Ashikaga T, Higgins T, Lenox S, Silberman S, Ferguson W. Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB). ASCO Meeting Abstracts 2011; 29:9554.